| 36.6209 -0.239 (-0.65%) | 01-30 15:25 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 43.91 |
1-year : | 46.01 |
| Resists | First : | 37.59 |
Second : | 39.4 |
| Pivot price | 36.85 |
|||
| Supports | First : | 34.68 | Second : | 28.85 |
| MAs | MA(5) : | 37.08 |
MA(20) : | 36.95 |
| MA(100) : | 33.39  |
MA(250) : | 33.79 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 44.7 |
D(3) : | 50.6 |
| RSI | RSI(14): 47.5 |
|||
| 52-week | High : | 40.86 | Low : | 25.52 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ HRMY ] has closed above bottom band by 44.4%. Bollinger Bands are 45% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 37.12 - 37.27 | 37.27 - 37.4 |
| Low: | 36.02 - 36.2 | 36.2 - 36.36 |
| Close: | 36.55 - 36.84 | 36.84 - 37.1 |
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
Thu, 29 Jan 2026
Is Harmony Biosciences (HRMY) a Solid Growth Stock? 3 Reasons to Think "Yes" - sharewise.com
Thu, 29 Jan 2026
Insider Sell: Sandip Kapadia Sells Shares of Harmony Biosciences Holdings Inc (HRMY) - GuruFocus
Wed, 28 Jan 2026
Sandip Kapadia, Harmony Biosciences CFO, sells $139k in HRMY stock - Investing.com
Wed, 28 Jan 2026
How Harmony Biosciences Can Prove Its Skeptics Wrong - Finviz
Wed, 28 Jan 2026
The Bull Case For Harmony Biosciences (HRMY) Could Change Following Wakix Strength Amid Mounting Legal Challenges - simplywall.st
Wed, 28 Jan 2026
Harmony Biosciences: Still Undervalued But Unappealing Risk/Reward (Downgrade) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 58 (M) |
| Shares Float | 51 (M) |
| Held by Insiders | 12.1 (%) |
| Held by Institutions | 90.5 (%) |
| Shares Short | 4,350 (K) |
| Shares Short P.Month | 4,410 (K) |
| EPS | 3.17 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 14.5 |
| Profit Margin | 22.4 % |
| Operating Margin | 27.3 % |
| Return on Assets (ttm) | 13.1 % |
| Return on Equity (ttm) | 25.9 % |
| Qtrly Rev. Growth | 28.7 % |
| Gross Profit (p.s.) | 11.14 |
| Sales Per Share | 14.33 |
| EBITDA (p.s.) | 4.33 |
| Qtrly Earnings Growth | 10.1 % |
| Operating Cash Flow | 298 (M) |
| Levered Free Cash Flow | 188 (M) |
| PE Ratio | 11.57 |
| PEG Ratio | 0 |
| Price to Book value | 2.52 |
| Price to Sales | 2.55 |
| Price to Cash Flow | 7.09 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|